Clinical trial
Proof of Mechanism Study of GSK2330811 in Diffuse Cutaneous Systemic Sclerosis
NCT03041025
Study timeline
Study start (actual)2017-06-05Date precision: day
Registry last updated2021-05-24
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Scleroderma, Systemicunresolved
Interventions
GSK2330811DRUG
PlaceboDRUG
Sponsors & collaborators
GlaxoSmithKlinelead sponsor
Mapped research locations
BostonMassachusetts, United States1ChicagoIllinois, United States1Los AngelesCalifornia, United States1BaltimoreMaryland, United States1TorontoOntario, Canada1LondonUnited Kingdom1Ann ArborMichigan, United States1StanfordCalifornia, United States1BirminghamUnited Kingdom1NijmegenNetherlands1LeedsUnited Kingdom1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03041025 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.